GENENTECH, INC for GENENTECH INC
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Monitoring of the FY 14 appropriations bills and issues related to comprehensive tax reform; R&D Tax Credit issues; S. 3521, Family and Business Tax Cut Certainty Act of 2012; S. 1577 Greater Research Opportunities with Tax Help Act; H.R. 942, American Research and Competitiveness Act of 2011; H.R. 8; Research and Development Tax credit, general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned US corporations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| DARIN GARDNER | Sr. Director |
| ELI KOGAN | Assistant Director |
Health Issues HCR
Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations.; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; compounding issues; FY 13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942 S. 1577; S. 3187; Pedigree and biologics issues; H.R. 905: ASP issues; H.R. 5651; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Avastin-use in breast cancer treatment: general patient reform isse: implementation of the Affordable Care Act of 2010; Issues relating to the treatment of biologics in international health programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director |
| ELI KOGAN | Assistant Director |
| EVAN MORRIS | Vice President of Government Affairs |
| KATHERINE RAAB | Director |
Medicare/Medicaid MMM
Part B reimbursement; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Medicare coverage and payment of Part B drugs and bilogicals; Implementation issues related to Medicare and Medicare reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cance biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| EVAN MORRIS | Vice President of Government Affairs |
| KATHERINE RAAB | Director |
Budget/Appropriations BUD
FY13 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs, hepatitis screening, care and treatment, and access to breast cancer treatment; Following issues related to the budget and appropriations process FY 13 appropriations for FDA as well as the potential outcomes for negotiations on altering sequestration targets via legislation; Issues related to FDA & HHS program funding, FY13 Labor Health and Human Services, and Education, and Related Agencies Appropriations bills.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| DARIN GARDNER | Sr. Director |
Pharmacy PHA
Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare prescription drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010- Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit. Public Law 112-144, the Food and Drug Administration Safety and Innovation Act - legislation related to re-authorization of user fees for prescription drug, medical device, and biologics approval. Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director |
| EVAN MORRIS | Vice President of Government Affairs |
| KATHERINE RAAB | Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.